What's new? Log in Free sign up

Immatics (IMTX) News and press releases

Company Profile

News

From Benzinga Pro

Chardan Capital Maintains Buy on Immatics, Lowers Price Target to $25

News, Price Target, Analyst Ratings

Chardan Capital analyst Geulah Livshits maintains Immatics (NASDAQ:IMTX) with a Buy and lowers the price target from $28 to $25.

First Majestic Silver, Immatics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Immatics Biotechnologies Granted U.S. Patent #11597752: Peptides And Combination Of Peptides And Scaffolds Thereof For Use In Immunotherapy Against Colorectal Carcinoma And Other Cancers

https://www.scribd.com/document/629913565/IMTX-Patent

Immatics Biotechnologies Granted U.S. Patent #11559550: Peptides And Combination Of Peptides For Use In Immunotherapy Against Leukemias And Other Cancers

https://www.scribd.com/document/621632292/IMTX-Patent

Immatics Biotechnologies Granted U.S. Patent #11554164: A*03 Restricted Peptides For Use In Immunotherapy Against Cancers And Related Methods

https://www.scribd.com/document/620318568/IMTX-Patent

Immatics Biotechnologies Granted U.S. Patent #11542303: Peptides and combination thereof for use in the immunotherapy against cancers

https://www.scribd.com/document/617594407/IMTX-Patent

Press releases

From Benzinga Pro

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Earnings, Press Releases

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase 1b in

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

- Seed round co-led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio enables maturation of platform and pipeline towards first clinical evaluation Seamless Therapeutics today announced a

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.